NAMA
Nikko Asset Management Americas’s Recursion Pharmaceuticals RXRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $41.2M | Sell |
8,167,745
-239,589
| -3% | -$1.21M | 0.41% | 51 |
|
|
2025
Q1 | $44.4M | Sell |
8,407,334
-501,317
| -6% | -$2.65M | 0.57% | 46 |
|
|
2024
Q4 | $60.1M | Sell |
8,908,651
-786,127
| -8% | -$5.31M | 0.65% | 40 |
|
|
2024
Q3 | $63.9M | Sell |
9,694,778
-239,713
| -2% | -$1.58M | 0.72% | 38 |
|
|
2024
Q2 | $74.3M | Sell |
9,934,491
-428,312
| -4% | -$3.2M | 0.86% | 31 |
|
|
2024
Q1 | $103M | Buy |
10,362,803
+1,159,023
| +13% | +$11.5M | 1.02% | 29 |
|
|
2023
Q4 | $90.6M | Buy |
9,203,780
+5,680,656
| +161% | +$55.9M | 0.87% | 31 |
|
|
2023
Q3 | $27M | Buy |
3,523,124
+2,685,724
| +321% | +$20.5M | 0.32% | 55 |
|
|
2023
Q2 | $6.25M | Buy |
837,400
+335,423
| +67% | +$2.5M | 0.07% | 105 |
|
|
2023
Q1 | $3.3M | Buy |
501,977
+47,455
| +10% | +$312K | 0.04% | 126 |
|
|
2022
Q4 | $3.5M | Sell |
454,522
-36,218
| -7% | -$279K | 0.05% | 126 |
|
|
2022
Q3 | $5.16M | Buy |
490,740
+90,839
| +23% | +$955K | 0.07% | 112 |
|
|
2022
Q2 | $3.24M | Sell |
399,901
-15,367
| -4% | -$125K | 0.04% | 137 |
|
|
2022
Q1 | $2.82M | Buy |
415,268
+46,274
| +13% | +$314K | 0.02% | 152 |
|
|
2021
Q4 | $6.32M | Sell |
368,994
-40,200
| -10% | -$689K | 0.03% | 128 |
|
|
2021
Q3 | $8.59M | Buy |
409,194
+173,348
| +74% | +$3.64M | 0.04% | 127 |
|
|
2021
Q2 | $8.61M | Buy |
+235,846
| New | +$8.61M | 0.03% | 136 |
|